Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Liver Diseases

  Free Subscription


Articles published in N Engl J Med

Retrieve available abstracts of 74 articles:
HTML format



Single Articles


    October 2024
  1. SJOHOLM A, Mahma H
    Glycogenic Hepatopathy.
    N Engl J Med. 2024;391:1528.
    PubMed    


  2. MEI Z, Pu J, Shao Z
    Two Trials of Therapeutics for MASH with Liver Fibrosis.
    N Engl J Med. 2024;391:1461-1462.
    PubMed    


  3. POLYZOS SA
    Two Trials of Therapeutics for MASH with Liver Fibrosis.
    N Engl J Med. 2024;391:1461.
    PubMed    


    September 2024
  4. COHEN PA, Broad Leib EM
    Ingesting Risk - The FDA and New Food Ingredients.
    N Engl J Med. 2024;391:875-877.
    PubMed    


    August 2024
  5. HERNANDEZ PEREZ JM
    Alpha(1)-Antitrypsin Deficiency.
    N Engl J Med. 2024;391:e16.
    PubMed    


    July 2024
  6. KANWAL F
    Dual Agonists for Management of Metabolic Dysfunction-Associated Steatohepatitis.
    N Engl J Med. 2024;391:371-372.
    PubMed    


  7. SANYAL AJ, Bedossa P, Fraessdorf M, Neff GW, et al
    A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis.
    N Engl J Med. 2024;391:311-319.
    PubMed     Abstract available


  8. SCHUBACH A, Carr RM, Abdelmalek MF
    Hepatologist Consultation in Low-Risk MASLD.
    N Engl J Med. 2024;391:373-375.
    PubMed    


    June 2024
  9. GANAPATHI L, Cochran RL, Robbins GK, Barmettler S, et al
    Case 20-2024: A 73-Year-Old Man with Recurrent Fever and Liver Lesions.
    N Engl J Med. 2024;390:2309-2319.
    PubMed    


  10. LOOMBA R, Hartman ML, Lawitz EJ, Vuppalanchi R, et al
    Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis.
    N Engl J Med. 2024 Jun 8. doi: 10.1056/NEJMoa2401943.
    PubMed     Abstract available


    May 2024
  11. KOWDLEY KV, Levy C, Jones D
    Phase 3 Trials of Elafibranor and Seladelpar for Primary Biliary Cholangitis. Reply.
    N Engl J Med. 2024;390:1935-1936.
    PubMed    


  12. HIRSCHFIELD GM, Kremer AE, Levy C
    Phase 3 Trials of Elafibranor and Seladelpar for Primary Biliary Cholangitis. Reply.
    N Engl J Med. 2024;390:1934-1935.
    PubMed    


  13. IJICHI H
    Phase 3 Trials of Elafibranor and Seladelpar for Primary Biliary Cholangitis.
    N Engl J Med. 2024;390:1934.
    PubMed    


  14. AREVALO-CANAS C, Arevalo-Serrano J
    Phase 3 Trials of Elafibranor and Seladelpar for Primary Biliary Cholangitis.
    N Engl J Med. 2024;390:1933-1934.
    PubMed    


  15. NAJEM M, Dong E
    Esophageal Varices, White-Nipple Sign, and Portal Hypertensive Gastropathy.
    N Engl J Med. 2024;390:e47.
    PubMed    


  16. HARRISON SA, Taub R
    A Phase 3 Trial of Resmetirom in NASH with Liver Fibrosis. Reply.
    N Engl J Med. 2024;390:1632-1633.
    PubMed    


  17. SABET A
    A Phase 3 Trial of Resmetirom in NASH with Liver Fibrosis.
    N Engl J Med. 2024;390:1632.
    PubMed    


    February 2024
  18. SCHNABL B
    PPAR Agonists in Primary Biliary Cholangitis.
    N Engl J Med. 2024;390:855-858.
    PubMed    


  19. HIRSCHFIELD GM, Bowlus CL, Mayo MJ, Kremer AE, et al
    A Phase 3 Trial of Seladelpar in Primary Biliary Cholangitis.
    N Engl J Med. 2024;390:783-794.
    PubMed     Abstract available


  20. ASSIS DN
    Advancing Second-Line Treatment for Primary Biliary Cholangitis.
    N Engl J Med. 2024;390:853-854.
    PubMed    


  21. CUSI K
    Selective Agonists of Thyroid Hormone Receptor Beta for the Treatment of NASH.
    N Engl J Med. 2024;390:559-561.
    PubMed    


  22. HARRISON SA, Bedossa P, Guy CD, Schattenberg JM, et al
    A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis.
    N Engl J Med. 2024;390:497-509.
    PubMed     Abstract available


    December 2023
  23. CAI S, Kuang M
    Clonorchis sinensis Liver Flukes.
    N Engl J Med. 2023;389:e57.
    PubMed    


  24. LOOMBA R, Mansbach H, Margalit M
    Randomized Trial of Pegozafermin in NASH. Reply.
    N Engl J Med. 2023;389:2210.
    PubMed    


  25. PATOULIAS D
    Randomized Trial of Pegozafermin in NASH.
    N Engl J Med. 2023;389:2209-2210.
    PubMed    


    November 2023
  26. ROBBINS J, Halegoua-DeMarzio D, Basu Mallick A, Vijayvergia N, et al
    Liver Transplantation in a Woman with Mahvash Disease.
    N Engl J Med. 2023;389:1972-1978.
    PubMed     Abstract available


  27. KOWDLEY KV, Bowlus CL, Levy C, Akarca US, et al
    Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis.
    N Engl J Med. 2023 Nov 13. doi: 10.1056/NEJMoa2306185.
    PubMed     Abstract available


    September 2023
  28. RINELLA ME
    Pegozafermin for NASH - A Sprint to Start a Marathon.
    N Engl J Med. 2023;389:1044-1046.
    PubMed    


  29. LOOMBA R, Sanyal AJ, Kowdley KV, Bhatt DL, et al
    Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH.
    N Engl J Med. 2023;389:998-1008.
    PubMed     Abstract available


  30. ROBERTS EA, Schilsky ML
    Current and Emerging Issues in Wilson's Disease.
    N Engl J Med. 2023;389:922-938.
    PubMed    


    August 2023
  31. VALLA DC, Garcia-Pagan JC
    Primary Budd-Chiari Syndrome. Reply.
    N Engl J Med. 2023;389:10.
    PubMed    


  32. BORSANI O, Pietra D, Rumi E
    Primary Budd-Chiari Syndrome.
    N Engl J Med. 2023;389:10.
    PubMed    


    July 2023
  33. DAUVILLIERS Y, Mignot E, Del Rio Villegas R, Du Y, et al
    Oral Orexin Receptor 2 Agonist in Narcolepsy Type 1.
    N Engl J Med. 2023;389:309-321.
    PubMed     Abstract available


    June 2023
  34. BALWANI M, Desnick RJ, Belongie K
    Dersimelagon in Erythropoietic Protoporphyrias. Reply.
    N Engl J Med. 2023;388:2492-2493.
    PubMed    


  35. BARMAN-AKSOZEN J, Langendonk JG
    Dersimelagon in Erythropoietic Protoporphyrias.
    N Engl J Med. 2023;388:2492.
    PubMed    


  36. GRANATA F, Dechant C, Falchetto R
    Dersimelagon in Erythropoietic Protoporphyrias.
    N Engl J Med. 2023;388:2491-2492.
    PubMed    


    April 2023
  37. BALWANI M, Bonkovsky HL, Levy C, Anderson KE, et al
    Dersimelagon in Erythropoietic Protoporphyrias.
    N Engl J Med. 2023;388:1376-1385.
    PubMed     Abstract available


  38. GARCIA-PAGAN JC, Valla DC
    Primary Budd-Chiari Syndrome.
    N Engl J Med. 2023;388:1307-1316.
    PubMed    


    February 2023
  39. NADIM MK, Garcia-Tsao G
    Acute Kidney Injury in Patients with Cirrhosis.
    N Engl J Med. 2023;388:733-745.
    PubMed    


  40. BHAN I, Schaefer EA, Bradley WR, Rodriguez-Lopez JM, et al
    Case 4-2023: A 56-Year-Old Man with Abnormal Results on Liver Testing.
    N Engl J Med. 2023;388:544-554.
    PubMed    


  41. JU H, Liu C
    Cerebral Alveolar Echinococcosis.
    N Engl J Med. 2023;388:453.
    PubMed    


    January 2023
  42. GOYAL L, Meric-Bernstam F, Hollebecque A, Valle JW, et al
    Futibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma.
    N Engl J Med. 2023;388:228-239.
    PubMed     Abstract available


    December 2022
  43. VIEDMA-MARTINEZ M, Villegas Romero I
    Skin Necrosis after Transarterial Chemoembolization.
    N Engl J Med. 2022;387:2268.
    PubMed    


  44. OLYNYK JK, Ramm GA
    Hemochromatosis.
    N Engl J Med. 2022;387:2159-2170.
    PubMed    


    August 2022
  45. STRNAD P, Mandorfer M, Choudhury G, Griffiths W, et al
    Fazirsiran for Liver Disease Associated with Alpha1-Antitrypsin Deficiency.
    N Engl J Med. 2022;387:514-524.
    PubMed     Abstract available


    July 2022
  46. VERWEIJ N, Haas ME, Nielsen JB, Sosina OA, et al
    Germline Mutations in CIDEB and Protection against Liver Disease.
    N Engl J Med. 2022;387:332-344.
    PubMed     Abstract available


    January 2022
  47. PATEL A, Tillman BF
    Spur-Cell Hemolytic Anemia.
    N Engl J Med. 2022;386:e6.
    PubMed    


  48. SANYAL AJ, Van Natta ML, Tonascia J
    Nonalcoholic Fatty Liver Disease. Reply.
    N Engl J Med. 2022;386:296.
    PubMed    


  49. FRANCQUE SM, Bedossa P, Abdelmalek MF
    Nonalcoholic Fatty Liver Disease. Reply.
    N Engl J Med. 2022;386:295-296.
    PubMed    


  50. MIR BA, Majeed T, Chauhan A
    Nonalcoholic Fatty Liver Disease.
    N Engl J Med. 2022;386:295.
    PubMed    


  51. XIA ML, Wang H
    Nonalcoholic Fatty Liver Disease.
    N Engl J Med. 2022;386:294-295.
    PubMed    


  52. HORN P, Newsome PN
    Nonalcoholic Fatty Liver Disease.
    N Engl J Med. 2022;386:294.
    PubMed    


    December 2021
  53. WILLETT LL, Bromberg GK, Chung R, Leaf RK, et al
    Case 38-2021: A 76-Year-Old Woman with Abdominal Pain, Weight Loss, and Memory Impairment.
    N Engl J Med. 2021;385:2378-2388.
    PubMed    


    November 2021
  54. CHAPMAN MM, Muse VV, Mojica JE, Anahtar MN, et al
    Case 35-2021: A 50-Year-Old Woman with Pain in the Left Upper Quadrant and Hypoxemia.
    N Engl J Med. 2021;385:1995-2001.
    PubMed    


    October 2021
  55. GARCIA-TSAO G
    Nonalcoholic Steatohepatitis - Opportunities and Challenges.
    N Engl J Med. 2021;385:1615-1617.
    PubMed    


  56. SANYAL AJ, Van Natta ML, Clark J, Neuschwander-Tetri BA, et al
    Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease.
    N Engl J Med. 2021;385:1559-1569.
    PubMed     Abstract available


  57. FRANCQUE SM, Bedossa P, Ratziu V, Anstee QM, et al
    A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH.
    N Engl J Med. 2021;385:1547-1558.
    PubMed     Abstract available


    September 2021
  58. CHANDRA A, Bhattacharjee MS
    Kayser-Fleischer Rings in Wilson's Disease.
    N Engl J Med. 2021;385:e46.
    PubMed    


  59. BAJAJ JS, Kamath PS, Reddy KR
    The Evolving Challenge of Infections in Cirrhosis. Reply.
    N Engl J Med. 2021;385:1151-1152.
    PubMed    


  60. HAIDAR G, Singh N
    The Evolving Challenge of Infections in Cirrhosis.
    N Engl J Med. 2021;385:1150-1151.
    PubMed    


    August 2021
  61. ZOU Q, Li Y
    Hypervirulent Klebsiella pneumoniae.
    N Engl J Med. 2021;385:833.
    PubMed    


  62. FREDRICK TW, Neto MBB, Johnsrud DO, Camilleri M, et al
    Turning Purple with Pain.
    N Engl J Med. 2021;385:549-554.
    PubMed    


    July 2021
  63. KELLEY RK, Greten TF
    Hepatocellular Carcinoma - Origins and Outcomes.
    N Engl J Med. 2021;385:280-282.
    PubMed    


  64. BUTTERS CT, Nash M
    Infantile Hepatic Hemangiomas.
    N Engl J Med. 2021;385:e10.
    PubMed    


  65. NEWSOME PN, Sejling AS, Sanyal AJ
    Semaglutide or Placebo for Nonalcoholic Steatohepatitis. Reply.
    N Engl J Med. 2021;385:e6.
    PubMed    


  66. DA BL, Satapathy SK
    Semaglutide or Placebo for Nonalcoholic Steatohepatitis.
    N Engl J Med. 2021;385:e6.
    PubMed    


    June 2021
  67. BAJAJ JS, Kamath PS, Reddy KR
    The Evolving Challenge of Infections in Cirrhosis.
    N Engl J Med. 2021;384:2317-2330.
    PubMed    


  68. WONG F, Curry MP, Sanyal AJ
    Randomized Trials of Interventions for Hospitalized Patients with Cirrhosis. Reply.
    N Engl J Med. 2021;384:e90.
    PubMed    


  69. CHINA L, Freemantle N, O'Brien A
    Randomized Trials of Interventions for Hospitalized Patients with Cirrhosis. Reply.
    N Engl J Med. 2021;384:e90.
    PubMed    


  70. RATHI S, Kalantri A, Kalantri S
    Randomized Trials of Interventions for Hospitalized Patients with Cirrhosis.
    N Engl J Med. 2021;384:e90.
    PubMed    


  71. CHAUHAN A, Sharma S, Saraya A
    Randomized Trials of Interventions for Hospitalized Patients with Cirrhosis.
    N Engl J Med. 2021;384:e90.
    PubMed    


  72. ELFEKI MA, O'Shea R, Carey WD
    Randomized Trials of Interventions for Hospitalized Patients with Cirrhosis.
    N Engl J Med. 2021;384:e90.
    PubMed    


    April 2021
  73. COHN A, Nehs M, Chan J, Vaidya A, et al
    Casting a Wide Net.
    N Engl J Med. 2021;384:e50.
    PubMed    


  74. MCINNES IB, Anderson JK, Magrey M, Merola JF, et al
    Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis.
    N Engl J Med. 2021;384:1227-1239.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Liver Diseases is free of charge.